FY2026 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Wedbush raised their FY2026 EPS estimates for Disc Medicine in a report issued on Tuesday, January 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($3.96) for the year, up from their prior forecast of ($4.19). Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15.

A number of other brokerages have also recently weighed in on IRON. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday. Stifel Nicolaus lifted their target price on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. Scotiabank increased their price target on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a research report on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $88.50.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $55.79 on Thursday. The stock has a 50-day simple moving average of $62.73 and a 200-day simple moving average of $53.69. The stock has a market capitalization of $1.66 billion, a P/E ratio of -13.99 and a beta of 0.75. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60.

Insider Activity at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 9,158 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $59.64, for a total transaction of $546,183.12. Following the completion of the transaction, the insider now owns 40,405 shares in the company, valued at approximately $2,409,754.20. The trade was a 18.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,758 shares of company stock valued at $5,400,990 over the last ninety days. Corporate insiders own 4.24% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently made changes to their positions in the stock. Amalgamated Bank lifted its holdings in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the period. Quest Partners LLC bought a new stake in Disc Medicine in the third quarter valued at $131,000. Quantbot Technologies LP acquired a new position in shares of Disc Medicine during the third quarter valued at $146,000. Finally, Intech Investment Management LLC bought a new position in shares of Disc Medicine during the third quarter worth about $228,000. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.